COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspective.
COVID-19
cancer
clinical trials
oncology
pandemic
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
11
05
2020
revised:
05
06
2020
accepted:
16
06
2020
pubmed:
11
7
2020
medline:
18
12
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic changed health-care operations around the world and has interrupted standard clinical practices as well as created clinical research challenges for cancer patients. Cancer patients are uniquely susceptible to COVID-19 infection and have some of the worst outcomes. Importantly, cancer therapeutics could potentially render cancer patients more susceptible to demise from COVID-19 yet the poor survival outcome of many cancer diagnoses outweighs this risk. In addition, the pandemic has resulted in risks to health-care workers and research staff driving important change in clinical research operations and procedures. Remote telephone and video visits, remote monitoring, electronic capture of signatures and data, and limiting sample collections have allowed the leadership in our institution to ensure the safety of our staff and patients while continuing critical clinical research operations. Here we discuss some of these unique challenges and our response to change that was necessary to continue cancer clinical research; and, the impacts the pandemic has caused including increases in efficiency for our cancer research office.
Identifiants
pubmed: 32648667
doi: 10.1002/cam4.3292
pmc: PMC7404529
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6141-6146Subventions
Organisme : American Cancer Society
ID : RSG-19-111-01-CCE
Pays : International
Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
JCO Oncol Pract. 2020 Jun;16(6):319-325
pubmed: 32160138
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Cancer Med. 2020 Sep;9(17):6141-6146
pubmed: 32648667
Lancet Haematol. 2020 Jun;7(6):e432-e435
pubmed: 32339482
JCO Oncol Pract. 2020 Jul;16(7):417-421
pubmed: 32396491
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069